Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Lifted by Arizona State Retirement System

Arizona State Retirement System raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 31,293 shares of the biopharmaceutical company’s stock after buying an additional 550 shares during the quarter. Arizona State Retirement System’s holdings in Regeneron Pharmaceuticals were worth $32,890,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of REGN. Brown Lisle Cummings Inc. grew its position in Regeneron Pharmaceuticals by 18.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 10 shares during the last quarter. Team Hewins LLC increased its position in Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 11 shares during the period. Angeles Wealth Management LLC boosted its position in Regeneron Pharmaceuticals by 3.5% during the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after acquiring an additional 11 shares during the period. TrinityPoint Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 4.8% in the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 12 shares in the last quarter. Finally, Western Financial Corp CA increased its holdings in shares of Regeneron Pharmaceuticals by 0.7% during the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after purchasing an additional 12 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now owns 17,882 shares in the company, valued at $18,941,329.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Bonnie L. Bassler sold 756 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders sold a total of 20,625 shares of company stock worth $22,298,963 in the last three months. 7.48% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Piper Sandler upped their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target for the company. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,108.95.

Regeneron Pharmaceuticals Trading Down 2.4 %

Shares of NASDAQ REGN opened at $1,150.56 on Friday. The business has a 50-day moving average price of $1,111.49 and a two-hundred day moving average price of $1,018.40. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The firm has a market capitalization of $126.84 billion, a PE ratio of 33.99, a PEG ratio of 3.13 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the business posted $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.